|View printer-friendly version|
|Gilead Sciences Announces Executive Promotions|
– Gregg Alton Appointed Chief Patient Officer –
Mr. Alton joined the company nearly 20 years ago and was the architect
of its access program, which has enabled Gilead’s HIV medicines to reach
more than 11 million people in the developing world. He has helped shape
the organization in a number of executive positions, including as
general counsel, and more recently, leading the company’s international
commercial operations and corporate affairs groups. Prior to joining
Gilead, he was an attorney at the law firm of
“Gregg has a deep and broad understanding of the company and an
unparalleled commitment to enabling access to our medicines for millions
of people in both the developed and developing world,” said John F.
Dr. Brainard joined Gilead in 2010. She has extensive training and
experience in immunology, infectious diseases and drug development.
Under her leadership, Gilead received regulatory approval of four
chronic hepatitis C virus (HCV) therapies in a period of less than four
years. She was promoted to Vice President, Clinical Research, Liver
Diseases, in 2015. Dr. Brainard received a bachelor’s degree from
“Diana is an astute, knowledgeable and experienced clinician and
researcher with broad expertise across the field of infectious diseases.
She played an instrumental role in the rapid clinical development and
approval of Gilead’s HCV medicines,” said
Dr. Cheng joined Gilead in 1999 to lead the company’s development-stage programs in HIV/AIDS. He received additional responsibility for the company’s Development Operations organization in 2009 and was named Executive Vice President in 2015. Dr. Cheng was appointed Chief Medical Officer in March.
“During his time at Gilead, Andrew played a definitive role in bringing
forward new medicines that transformed the lives of millions of people
with serious illnesses,” said Dr.
Dr. Cheng will remain at Gilead until
This press release includes forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995 that are
subject to risks, uncertainties, and other factors. These risks,
uncertainties and other factors could cause actual results to differ
materially from those referred to in the forward-looking statements. The
reader is cautioned not to rely on these forward-looking statements.
These and other risks are described in detail in Gilead’s Quarterly
Report on Form 10-Q for the quarter ended
For more information on Gilead Sciences, please visit the company’s website at www.gilead.com, follow Gilead on Twitter (@GileadSciences) or call Gilead Public Affairs at 1-800-GILEAD-5 or 1-650-574-3000.
Gilead Sciences, Inc.
Minimum 20 minute delay